| Iupac Name: | N-(3-((2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)furo[3,2-''d'']pyrimidin-4-yl)oxy)phenyl)acrylamide |
| Cas Number: | 1353552-97-2 |
| Unii: | D01E4B1U35 |
| Pubchem: | 56644522 |
| Synonyms: | HM-7122; LY 3337641 |
| C: | 26 |
| H: | 26 |
| N: | 6 |
| O: | 3 |
| Smiles: | C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1 |
| Stdinchi: | 1S/C26H26N6O3/c1-3-23(33)27-19-5-4-6-21(17-19)35-25-24-22(11-16-34-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30) |
| Stdinchikey: | LZMJNVRJMFMYQS-UHFFFAOYSA-N |
Poseltinib (HM71224, LY3337641) is an experimental Bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis. It was developed by Hanmi Pharmaceutical and licensed to Eli Lilly.[1]
Phase II clinical trials began in August 2016 in patients with rheumatoid arthritis. Additional phase II trials are planned for treatment of lupus, lupus nephritis, Sjögren's syndrome, and other immunological conditions.[2]